12:00 AM
 | 
Apr 21, 2008
 |  BioCentury  |  Strategy

Sticking to front-end value

Since it was founded in 2004, Codon Devices Inc. has used its BioFAB technology to provide synthetic gene constructs on a fee-for-service basis to customers in the pharmaceutical, agbiotech and industrial biotech markets. Last week, the synthetic biology company entered its first deal for biopharma product development with Merrimack Pharmaceuticals Inc.

Codon will use its BioLOGIC protein optimization platform,which encompasses and builds upon BioFAB, to design, synthesize and optimize full-length, functional therapeutic proteins against targets identified by Merrimack, according to Merrimack's specifications.

Merrimack will receive an exclusive license to develop and commercialize resulting proteins. In return, Codon receives an upfront fee and potential milestones and royalties.

Merrimack is developing therapeutics for autoimmune diseases and cancer. Its lead compound is MM-093, a recombinant human alpha-fetoprotein (AFP) that...

Read the full 642 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >